GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » FCF Margin %

Tourmaline Bio (Tourmaline Bio) FCF Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Tourmaline Bio FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Tourmaline Bio's Free Cash Flow for the three months ended in Mar. 2024 was $-14.92 Mil. Tourmaline Bio's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Tourmaline Bio's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.

As of today, Tourmaline Bio's current FCF Yield % is -11.38%.

The historical rank and industry rank for Tourmaline Bio's FCF Margin % or its related term are showing as below:


TRML's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -144.01
* Ranked among companies with meaningful FCF Margin % only.

Tourmaline Bio FCF Margin % Historical Data

The historical data trend for Tourmaline Bio's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tourmaline Bio FCF Margin % Chart

Tourmaline Bio Annual Data
Trend Dec21 Dec22 Dec23
FCF Margin %
- - -

Tourmaline Bio Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
FCF Margin % Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Tourmaline Bio's FCF Margin %

For the Biotechnology subindustry, Tourmaline Bio's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tourmaline Bio's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tourmaline Bio's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Tourmaline Bio's FCF Margin % falls into.


Tourmaline Bio FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Tourmaline Bio's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-28.137/0
= %

Tourmaline Bio's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-14.923/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tourmaline Bio FCF Margin % Related Terms

Thank you for viewing the detailed overview of Tourmaline Bio's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Tourmaline Bio (Tourmaline Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » FCF Margin %
Comparable Companies
CYTK NUVL KRYS CRSP INSM FOLD BPMC IMGN AXSM ACAD OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
27 West 24th Street, Suite 702, New York, NY, USA, 10010
Website
https://www.tourmalinebio.com
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.